A multicenter, randomized controlled trial is conducted to evaluate the safety of a novel oral anticoagulant (NOAC) compared to standard-of-care warfarin for stroke prevention in patients with nonvalvular atrial fibrillation and concurrent moderate chronic kidney disease. The study enrolls 2,400 patients, who are randomly assigned in a 1:1 ratio to receive either the NOAC or warfarin. All patients are followed for exactly two years. During the follow-up period, the primary safety endpoint of major gastrointestinal bleeding is assessed.
The investigators report the following safety data:
- NOAC group (): 54 patients experienced a major gastrointestinal bleed.
- Warfarin group (): 30 patients experienced a major gastrointestinal bleed.
Based on these study results, what is the number needed to harm (NNH) for major gastrointestinal bleeding associated with the NOAC compared to warfarin? (Enter your answer as a whole number).
Answer: 50 patients